2017
DOI: 10.1016/j.ebiom.2017.06.013
|View full text |Cite
|
Sign up to set email alerts
|

Gray Matter Abnormalities in Non-comorbid Medication-naive Patients with Major Depressive Disorder or Social Anxiety Disorder

Abstract: BackgroundAn overlap of clinical symptoms between major depressive disorder (MDD) and social anxiety disorder (SAD) suggests that the two disorders exhibit similar brain mechanisms. However, few studies have directly compared the brain structures of the two disorders. The aim of this study was to assess the gray matter volume (GMV) and cortical thickness alterations between non-comorbid medication-naive MDD patients and SAD patients.MethodsHigh-resolution T1-weighted images were acquired from 37 non-comorbid M… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

10
71
1
1

Year Published

2018
2018
2024
2024

Publication Types

Select...
6
2

Relationship

0
8

Authors

Journals

citations
Cited by 92 publications
(83 citation statements)
references
References 62 publications
10
71
1
1
Order By: Relevance
“…An extensive literature has shown that a wide range of psychiatric disorders, especially anxiety and depression, can accompany migraine [4,[47][48][49]. Previous studies revealed cortical abnormalities in depression [35,50,51] and anxiety disorders [52][53][54][55]. However, these psychiatric problems are often under-diagnosed and have not been thoroughly assessed in CTh studies in migraine.…”
Section: Discussionmentioning
confidence: 99%
“…An extensive literature has shown that a wide range of psychiatric disorders, especially anxiety and depression, can accompany migraine [4,[47][48][49]. Previous studies revealed cortical abnormalities in depression [35,50,51] and anxiety disorders [52][53][54][55]. However, these psychiatric problems are often under-diagnosed and have not been thoroughly assessed in CTh studies in migraine.…”
Section: Discussionmentioning
confidence: 99%
“…Based on previous findings, and as summarized in Bas-Hoogendam et al (2016) [ 48 ], there are two important reasons to do so. To start, differences in GM between SAD-patients and healthy controls have been reported for a number of subcortical, frontal, temporal and parietal regions [ 49 , 50 , 59 , 60 , [51] , [52] , [53] , [54] , [55] , [56] , [57] , [58] ] – see Table 1 for an overview of MRI-studies on GM in SAD. Furthermore, changes in brain structure were shown to be associated with clinical characteristics [ 49 , 50 , [54] , [55] , [56] , [57] , [58] , 60 , 61 ], while treatment-related changes in brain structure in SAD patients have also been described [ [62] , [63] , [64] ].…”
Section: Introductionmentioning
confidence: 99%
“… n.a. Talati et al, 2015 [ 62 ] Whole brain VBM (SPM) 14 SAD - treatment effect = = - After treatment - After treatment - After treatment Tükel et al, 2015 [ 56 ] Whole brain VBM (SPM) 27 SAD vs 27 HC = = = = = Månnson et al, 2016, 2017 [ 195 , 196 ] ROIs (amygdala, ACC, insula, hippocampus) as well as whole brain VBM (SPM) 13 SAD - treatment effect - After treatment = = = = Steiger et al, 2016 [ 63 ] Whole brain cortical volume & CT using Freesurfer 33 SAD -treatment effect = = = = = Bas-Hoogendam et al, 2017 [ 60 ] Whole brain VBM (FSL) 178 SAD vs 213 HC = = = + = Zhao et al, 2017 [ 59 ] Whole brain VBM (SPM) & whole brain CT using Freesurfer 24 SAD vs 41 HC (and 37 MDD) = = = Publication Frontal regions Parietal regions MPFC DLPFC VLPFC OFC PMC ACC PCC Par PC Potts et al, 1994 [ 193 ] n.a. n.a.…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…8 Emerging evidence from epidemiology, genetics, and clinical neuroimaging often does not support the current diagnoses codified in the DSM. [9][10][11] One alternative is to evaluate dimensions of symptoms that cross diagnostic boundaries. 12 However, dimensional models based on symptoms only do not take into account the neurobiological mechanisms underlying psychiatric symptoms.…”
Section: Introductionmentioning
confidence: 99%